Phase one will debut new eSource technology at the event, marking OptymEdge’s evolution into a full-service ophthalmic research partner

2nd May 2025 – OptymEdge, part of the Emmes Group, will unveil what it describes as the clinical research industry’s first technology platform dedicated exclusively to ophthalmology trials during ARVO 2025, taking place from May 4–8.

The launch marks a significant expansion of OptymEdge’s digital capabilities and represents the first phase of a wider rollout designed to enhance trial efficiency, improve data quality, and support sponsors with end-to-end ophthalmic research services. Initially, the platform will include support for Best Corrected Visual Acuity (BCVA), with additional visual function assessments planned as development progresses.

According to the company, the platform has been developed to address long-standing challenges associated with manual data entry and inconsistency in ophthalmology trials. OptymEdge said the new eSource solution will replace paper-based BCVA workflows with a digital system that guides users step-by-step through each assessment, reducing examiner variability and improving data integrity.

The platform will also feature full compatibility with Electronic Data Capture (EDC) systems, allowing secure, automated transfer of patient data without additional administrative burden for trial sites.

Phase one of the rollout will be demonstrated live at ARVO, where attendees will be able to explore the eSource technology first-hand. In future phases, OptymEdge plans to integrate AI-enhanced image analysis tools for trial image reading and develop a comprehensive digital network map of its global ophthalmology trial sites.

The initiative builds on OptymEdge’s decades-long history in BCVA certification and visual function endpoint expertise. The company said this foundation gives it a unique perspective on the operational challenges trial sponsors face and the tools needed to overcome them.

“For over 30 years, we’ve been at the forefront of BCVA certification in ophthalmic clinical trials,” said Saqib Parkar, managing director at OptymEdge.

“We saw a need to improve data quality, consistency, and efficiency by developing purpose-built technology platforms from the ground up. Our new eSource platform addresses long-standing challenges in manual BCVA data collection and marks a pivotal step in our transformation into a comprehensive ophthalmic research partner. As we expand beyond BCVA into additional ophthalmology endpoints, we’re committed to delivering greater standardization, scalability, and value to our partners through integrated digital solutions.”

In the coming months, OptymEdge plans to expand its service offering further with the launch of a global ophthalmology trial site network and the introduction of reading center services. The company believes these additions will help enhance sponsor visibility, improve image grading consistency, and deliver higher quality outcomes across studies.

OptymEdge said the combination of technology innovation and clinical trial expertise positions it to support both large and small sponsors with a unified, scalable model for conducting ophthalmology research—offering what it sees as a more streamlined, future-ready approach to drug development in this space.